colorectal cancer

Invitation to a conference call and webcast by Isofol in connection with the entered license agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

Uncategorized / By

GOTHENBURG, Sweden, November 2, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) has today announced a definitive licensing agreement with Endo Ventures Limited, a subsidiary of Endo International plc. (NASDAQ: ENDP) for the commercialization of arfolitixorin on an exclusive basis in Canada. With the consent of Isofol, Endo Ventures Limited has designated Paladin Labs Inc., an operating company of Endo, to be responsible for seeking regulatory approval for arfolitixorin in Canada and after receipt of such approval, to be responsible for the commercialization of arfolitixorin in Canada, including distribution, marketing, medical affairs, pricing and reimbursement activities. In connection with this, Isofol invites investors, analysts and media to a conference call and webcast on November 2, 2020 at 15:00 (CET).

Invitation to a conference call and webcast by Isofol in connection with the entered license agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada Read More »

Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

Pressmeddelande / By

GOTHENBURG, Sweden, November 2, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) is pleased to announce today a definitive license agreement with Endo Ventures Limited, a subsidiary of Endo International plc (NASDAQ: ENDP) plc, for the registration and commercialization of arfolitixorin on an exclusive basis in Canada. With the consent of Isofol, Endo Ventures Limited has designated Paladin Labs Inc., an operating company of Endo, to be responsible for seeking regulatory approval for arfolitixorin in Canada and after receipt of such approval, to be responsible for the commercialization of arfolitixorin in Canada, including distribution, marketing, medical affairs, pricing and reimbursement activities. Isofol may receive up to $US 23.05 million** (SEK 205 million**) as upfront, development, regulatory and sales-based milestone payments. In addition, Isofol will receive tiered royalties on net sales in solid double-digit figures.

Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada Read More »

Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

Pressmeddelande / By

GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from an open-label extension study for the ISO-CC-005 Phase 1/2a study of arfolitixorin in patients with metastatic colorectal cancer (mCRC). New results from 19 patients treated in the first-line setting showed early tumor shrinkage, defined as a greater than 20 % reduction in tumor size from baseline, in 47 % of patients (9/19) treated with the selected dose regimen, a combination of 120 mg/m² arfolitixorin and 5-fluorouracil (5-FU) with either irinotecan or oxaliplatin (ARFIRI/ARFOX).

Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin Read More »

Scroll to Top